Christopher Hillis

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 185 citations

Medicine, Hematology, Pharmacology +9

McMaster RARE‐Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome

Kimberly Legault, Holger J. Schünemann, Christopher Hillis et al. · Journal of Thrombosis and Haemostasis · 2018 · 140 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +8

Strategies for eliciting and synthesizing evidence for guidelines in rare diseases

Menaka Pai, Cindy H. T. Yeung, Elie A. Akl et al. · BMC Medical Research Methodology · 2019 · 108 citations · Full text

Medicine, Health Policy, Hematology +11

Gender and <i><scp>BCR</scp>‐<scp>ABL</scp></i> transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia

Hanxin Lin, Jenny Sjaarda, Jocob Dyck et al. · European Journal Of Haematology · 2015 · 43 citations

Medicine, Molecular Medicine, Oncology +8

Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease

Darryl P. Leong, Nazanin Aghel, Christopher Hillis et al. · Heart · 2021 · 20 citations

Medicine, Oncology, Pharmacology +16